Search
Paclitaxel Treatment Options in Indiana
A collection of 374 research studies where Paclitaxel is the interventional treatment. These studies are located in the Indiana, United States. Paclitaxel is used for conditions such as Breast Cancer, Ovarian Cancer and Non-Small Cell Lung Cancer.
121 - 132 of 374
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Study of Lonsurf in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Advanced (PDAC)
Terminated
The purpose of this study is to determine the recommended phase 2 dose (RP2D) of the combination of lonsurf, gemcitabine and nab-paclitaxel in Pancreatic ductal adenocarcinoma (PDAC)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/02/2024
Locations: Indiana University Melvin & Bren Simon Cancer Center, Indianapolis, Indiana
Conditions: Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma
Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery
Active Not Recruiting
Study to compare the safety and efficacy of oregovomab versus placebo, administered in combination with specific cycles of a standard six-cycle chemotherapy regimen (paclitaxel and carboplatin), for the treatment of subjects with newly diagnosed advanced ovarian cancer who have undergone optimal debulking.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/15/2023
Locations: Parkview Research Center, Fort Wayne, Indiana
Conditions: Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Ovarian Cancer, Ovarian Serous Adenocarcinoma, Fallopian Tube Neoplasms, Fallopian Tube Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Peritoneal Cancer, Peritoneal Carcinoma, Peritoneal Neoplasms
A Study of ABT-165 in Subjects With Solid Tumors
Completed
This is a Phase 1/1b open-label study evaluating the safety, pharmacokinetics (PK), and preliminary efficacy of ABT-165 when administered as monotherapy and in combination with paclitaxel or 5-fluoruracil, folinic acid and irinotecan (FOLFIRI) or ABBV-181 with/without paclitaxel in subjects with advanced solid tumors. Enrollment to Cohorts A, B were completed and for Cohorts C and D are recruiting.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
12/13/2023
Locations: Horizon Oncology Research Center /ID# 138022, Lafayette, Indiana
Conditions: Advanced Solid Tumors
Trial of Nivolumab With Chemotherapy as Neoadjuvant Treatment in Inflammatory Breast Cancer (IBC)
Completed
Study of efficacy of nivolumab with neoadjuvant chemotherapy in patients with IBC
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/28/2023
Locations: Indiana University, Bloomington, Indiana
Conditions: Breast Cancer
First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
Terminated
The purpose of this trial is to explore the activity and safety of everolimus +/- paclitaxel as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/21/2023
Locations: Cancer Care Center of Southern Indiana, Bloomington, Indiana +2 locations
Conditions: Transitional Cell Carcinoma, Bladder Carcinoma, Urothelial Carcinoma
Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors
Completed
The purpose of this study is to evaluate the safety, tolerability, and efficacy of single agent ibrutinib or the combination treatments of ibrutinib with everolimus, paclitaxel, docetaxel, pembrolizumab or cetuximab in selected advance gastrointestinal and genitourinary tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/14/2023
Locations: Franciscan Health Indianapolis /ID# 1128-1125, Indianapolis, Indiana +1 locations
Conditions: Metastatic Renal Cell Carcinoma, Advanced Urothelial Carcinoma, Advanced Gastric Adenocarcinoma, Metastatic Colorectal Adenocarcinoma
A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer
Completed
This is an open label, multi-center, multi-arm, dose-escalation study of BBI608 administered in combination with Gemcitabine and nab-Paclitaxel, mFOLFIRINOX, FOLFIRI, or MM-398 with 5-FU and leucovorin.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/13/2023
Locations: Parkview Research Center, Fort Wayne, Indiana +2 locations
Conditions: Metastatic Pancreatic Adenocarcinoma
A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma
Completed
This is a randomized, open-label, multi-center, phase 3 study of napabucasin plus weekly nab-paclitaxel with gemcitabine versus weekly nab-paclitaxel with gemcitabine for adult patients with Metastatic Pancreatic Ductal Adenocarcinoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/13/2023
Locations: Parkview Physician Group (PPG), Fort Wayne, Indiana +1 locations
Conditions: Carcinoma, Pancreatic Ductal
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Completed
This is an open label, single arm phase 1 dose escalation study and phase 2 study of BBI608 in combination with paclitaxel in patients with advanced malignancies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/13/2023
Locations: Indiana University Simon Cancer Center, Indianapolis, Indiana
Conditions: Cancer
A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer
Completed
The purpose of this study is to find out whether it is better to receive a new drug, BBI608, in addition to paclitaxel chemotherapy or better to receive paclitaxel chemotherapy alone as second line treatment for gastric and gastroesophageal junction cancer after prior first line platinum and fluoropyrimidine based chemotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/13/2023
Locations: Indiana University Health Goshen Center For Cancer Care, Goshen, Indiana +1 locations
Conditions: Gastric Cancer, Gastroesophageal Junction Cancer
A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer
Completed
This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the study is to determine the safety, tolerability, and RP2D of BBI503 in combination with each of the selected anti-cancer agents.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/13/2023
Locations: Parkview Research Center, Fort Wayne, Indiana +3 locations
Conditions: Cancer
Batiraxcept (AVB-S6-500)/Placebo in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer
Terminated
This is a randomized, double-blind Phase 3 study to compare the efficacy and safety of batiraxcept (AVB-S6-500) in combination with paclitaxel (PAC) versus placebo in combination with PAC in patients with platinum resistant recurrent ovarian cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
10/26/2023
Locations: Community Health Network, Indianapolis, Indiana +1 locations
Conditions: Platinum-resistant Ovarian Cancer
121 - 132 of 374